Loading cancer entity…
Loading cancer entity…
Clinical trials
144 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07743138 | STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04394858 | Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer | active not recruiting | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT03206060 | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma | recruiting | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07714551 | Zanzalintinib in Unresectable and Progressive MPGGs | not yet recruiting | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07680205 | An Experimental Study of Belzutifan Impact on Catecholamine Metabolism | recruiting | Phase 2 | 12 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07282587 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | recruiting | Phase 2 | 90 | Jazz PharmaceuticalsINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00107289 | Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | recruiting | Phase 2 | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT03839498 | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | active not recruiting | Phase 2 | 6 | Columbia UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03946527 | LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)(LAMPARA) | active not recruiting | Phase 2 | 10 | Antonio FojoOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04711135 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs(NETTER-P) | active not recruiting | Phase 2 | 11 | Advanced Accelerator ApplicationsINDUSTRY | 5 | Feb 12, 2026 | clinicaltrials |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma(Spencer) | terminated | Phase 1 / Phase 2 | 70 | EnteromeINDUSTRY | 8 | Jan 30, 2026 | clinicaltrials |
| NCT02302833 | Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study(CABATEN) | completed | Phase 2 | 93 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06429397 | Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma | not yet recruiting | Phase 2 | 22 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | withdrawn | Phase 2 | 0 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT00843037 | Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma(SNIPP) | completed | Phase 2 | 25 | University Health Network, TorontoOTHER | 2 | Oct 17, 2024 | clinicaltrials |
| NCT06045260 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC(LUFOR) | recruiting | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04860700 | The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma | completed | Phase 2 | 27 | Peking Union Medical College HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03008369 | Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05885399 | The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment | unknown | Phase 2 | 5 | Peking Union Medical College HospitalOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05885386 | A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05883085 | A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL | unknown | Phase 2 | 10 | Peking Union Medical College HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05858177 | The Efficacy and Safety of Temozolomide in Patients With MPPGL(MPPGL) | completed | Phase 2 | 62 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT04276597 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.(PUTNET) | withdrawn | Phase 2 | 0 | Excel Diagnostics and Nuclear Oncology CenterOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT01371201 | First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma(FIRSTMAPPP) | completed | Phase 2 | 78 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 4 | Aug 4, 2022 | clinicaltrials |
| NCT04320589 | the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma | completed | Phase 2 | 30 | National Cancer Institute, EgyptOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | withdrawn | Phase 1 / Phase 2 | 0 | Sue O'DorisioOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT01967576 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT01635907 | Dovitinib in Neuroendocrine Tumors | completed | Phase 2 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00874614 | A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | unknown | Phase 2 | 74 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01560260 | Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2018 | clinicaltrials |
| NCT01413503 | A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | completed | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01340794 | Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 3 | Sep 21, 2017 | clinicaltrials |
| NCT00028106 | 131MIBG to Treat Malignant Pheochromocytoma | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00458952 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | completed | Phase 1 / Phase 2 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT01152827 | RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid(PheoCarcRAD001) | completed | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT00002608 | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | completed | Phase 2 | 30 | Ottawa Regional Cancer CentreOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00466856 | Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | terminated | Phase 2 | 10 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 18, 2012 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials